Floatz logo

PEGASPARGASE

Recurrent T Lymphoblastic Leukemia/Lymphoma

Children's Oncology Groupprotein_peptidePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Recurrent T Lymphoblastic Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Children's Oncology Group
Phase 3BB
ETOPOSIDE
Children's Cancer Group, China
Phase 3BB
VINCRISTINE SULFATE
Children's Oncology Group
Phase 2/3B
Inno-206
Children's Oncology Group
Phase 2/3B
ASPARAGINASE
University of Washington
Phase 2CCC
Imatinib
University of Washington
Phase 2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 2CCC
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
University of Washington
Phase 2CCC

Same molecule, other indications

PEGASPARGASE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
80 / 100
View asset →
Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →